Abstract
IntroductionThis study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in estimating cancer incidence by comparing the results with the Beijing Cancer Registry (BCR), which is one of the highest-quality population-based cancer registries in China.MethodsUsing lymphoma as an example, we extracted relevant claims data from the administrative systems of medical insurance in Beijing (2012–2020) and estimated the most current lymphoma incidence in Beijing (2019) using a standard data processing procedure. The absolute number of new cases, crude incidence rate, and age-standardized incidence rate of lymphoma were compared with the latest data reported by the BCR (2017).ResultsBoth lymphoma incidence rates and age distribution of new cases estimated based on MIS-CASS were similar to the BCR data (crude incidence rate: 9.8/100,000 vs. 10.6/100,000). However, because MIS-CASS included more designated hospitals and covered a larger local stationary population irrespective of household registration (hukou), the absolute number of incident lymphoma cases identified by MIS-CASS was 39.1% higher than that reported by the BCR (2,002 vs. 1,439). ConclusionsThe MIS-CASS approach reflected the actual cancer burden in a more complete and timely manner as compared with the current BCR, providing new insights for improving cancer surveillance strategies in China.
Highlights
This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in estimating cancer incidence by comparing the results with the Beijing Cancer Registry (BCR), which is one of the highest-quality population-based cancer registries in China
The corresponding admission date of each lymphoma case was defined as its incidence date, which was in accordance with the BCR [10]
The lymphoma incidence in Beijing estimated by MIS-CASS was close to that reported by BCR (Table 1), and no significant difference in morphologic distribution was detected between MIS-CASS and BCR
Summary
This study aimed to evaluate the performance of the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in estimating cancer incidence by comparing the results with the Beijing Cancer Registry (BCR), which is one of the highest-quality population-based cancer registries in China. Population-based cancer registration is recognized as the gold standard for reporting cancer incidence in a defined population [1]. In China, the establishment of cancer registration dates back to the late 1950s, and currently, cancer registries cover approximately 43% of the population in the country [2]. Due to the vast territory, huge population, and limited resources of China, it is still difficult to establish a real nationwide population-based cancer registry (PBCR), and the quality of available cancer data showed significant variation across geographic areas [2]. Since the collection and ascertainment of incident cancer cases is labour intensive and time consuming under the current surveillance approach, the delay in reporting annual national cancer incidence statistics is often as long as 3 to 5 years [3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
